@inproceedings{inproceedings, title = {{A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guerin (BCG) therapy}}, url = {{}}, year = {{2020}}, month = {{1}}, author = {{Steinberg GD and Palou-Redorta J and Gschwend JE and Ben T and Loriot Y and Daneshmand S and Roupret M and Santiago-Walker AE and Switzky JC and Major C and Baig M et al}}, volume = {{38}}, journal = {{JOURNAL OF CLINICAL ONCOLOGY}}, issue = {{6}}, note = {{Accessed on 2025/05/28}}}